EVIDENCE BASED DECISION MAKING FOR THE RATIONAL DRUG LIST (RDL)

DR MAISA AL SAKET

DG JOINT PROCUREMENT DEPARTMENT

Committee 2 Evidence Based

MeTA 10/04/23 1

10/04/23MeTA 2

Members of Committee 2

Dr Maisa Al Saket/ G.D. - JPD Dr Riham Al Natheef/ Supply Director- RMS Dr Musallam Qatarneh/ Purchasing & Supply

Director/ MOH Dr Ibrahim Abbadi/ Jordan University Dr Lama Al Homoud/ Clinical Pharmacy Director -

MOH Dr Hanan Sboul/ SG. - JAPM

Background

There will be a transparent evidence- based process in place for listing drugs

Conducting Pharmaco-economic studies is crucial for the development of an effective and affordable national drug list

It is crucial that the public health institutions are supportive of the process and believe in the integrity of the final RDL in order to promote the adherence to it by prescribers and institutions  

10/04/23MeTA 3

MeTA Work plan- Jordan

Encouraging best practice/ improve rational use of medicines

Evidence based decision making for the rational drug list RDL

Capacity building in Civil society

10/04/23MeTA 4

Evidence- based decision making can be achieved through:

Assessment of Current Committees’ constitution, TOR and Procedures

Assessment of current classification of drugs Raising awareness among stakeholders and

building capacity Monitoring & evaluation

10/04/23MeTA 5

10/04/23MeTA 6

Assessment of Current Committees’ constitution, TOR and Proceduressub-activities: Review constitutions, TOR and SOPs of various

committees involved in the selection of drugs in the RDL (requires COI declaration, and COI guidelines) and benchmark against best practices

Recommend regulations for the amendments- if needed Review criteria for adding and deleting drugs to and

from the RDL Recommend evidence based regulations for the

addition / deletion criteria Adopt the recommendations

10/04/23MeTA 7

Assessment of current classification of drugs

• Formulate a technical working group to review the classification of drugs (restricted, unrestricted & authority required) in the RDL

• Recommend detailed evidence based regulations for the implementation of the classification of drugs

• Adopt the classification & the detailed regulations for the implementation of the classification

Technical working group represents

JFDA/ RDU JPD Ministry of Health/ Clinical Pharmacy , Supply Departments Royal Medical Services/ Drug &Pharmacy, Supply

Departments Academia/ PhD in clinical pharmacy Internal medicine consultant Pharmaco-economist

10/04/23MeTA 8

Raising awareness among stakeholders and building capacity

Organize workshops to raise awareness and reach a common understanding on the concepts of role of pharmacy & therapeutic committee (PTC), evidence-based medicine (EBM), pharmaco-economics, transparency & accountability

Train policy makers and technical committees in NICE/UK

Organize workshop on use of cost effectiveness tools

10/04/23MeTA 9

10/04/23MeTA 10

Monitoring and Evaluation

Monitor and Evaluate the adoption and implementation of recommendations in previous activities, according to set KPI’s

Evidence- based decision making activities KPI’s include:

Constitution, TOR & SOPs for committees are in place

Guidelines for addition/ deletion & classification are in place

Workshops conducted Reports to be delivered

10/04/23MeTA 11

Thank you

10/04/23MeTA 12